Diseases
Cala Announces FDA Clearance of Next-Gen Tremor Therapy Wearable
The Cala kIQ Plus device provides new therapy modes and adaptive calibration to optimize tremor relief for essential tremor and Parkinson's disease.
Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026
Clinical-stage PTK7 ADC KIVU-107 and next-generation CEACAM5 ADC KIVU-305 demonstrate promising preclinical results
Kivu Bioscience to Present Preclinical Data on Next-Gen ADC Programs
Promising results for PTK7 and CEACAM5 antibody-drug conjugates ahead of AACR 2026
- Freshworks and Klaviyo: A Business Comparison
- Gilead's New Lab Hub Reshapes Foster City's Vintage Park
- Short Interest in GoPro Drops by 15.1%
- Anonymous Threat Prompts Lockdown at San Mateo Elementary School
- SnapLogic Unveils AI Gateway and Trusted Agent Identity to Power Enterprise AI Execution
- Cala Announces FDA Clearance of Next-Gen Tremor Therapy Wearable
